Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.62 |
| ▸ | BPTF | Q12830 | 1/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19839303 | 1.00 | CHRNB2 (0.62) | CHRNB2CHRNA4BPTFCHRNB4CHRNA3 | |
| SCHEMBL19852376 | 0.89 | CHRNB4 (0.57) | CHRNB2CHRNA4BPTFCHRNB4CHRNA3 | |
| SCHEMBL1203405 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3SLC6A4 | |
| SCHEMBL16752694 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3NOTUM | |
| SCHEMBL15107330 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3SLC6A4 | |
| SCHEMBL6214829 | 0.79 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3HTR3E | |
| SCHEMBL6213085 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3NOTUM | |
| SCHEMBL7237162 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3ADRB1 | |
| Hydrochloric Acid SCHEMBL23302933 | 0.78 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3HTR3E | |
| Hydrochloric Acid SCHEMBL6214406 | 0.78 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| CN-119790053-A | Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors | 霖康疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119053595-A | Sulfonylamino derivatives as cyclin dependent kinase 2 inhibitors | 尼坎治疗公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | CHRNB2 4818/4885CHRNA4 4885/4885BPTF 803/4885 |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | CHRNB2 33/4885CHRNA4 51/4885BPTF 2707/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | CHRNB2 4818/4885CHRNA4 4885/4885BPTF 803/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | CHRNB2 33/4885CHRNA4 51/4885BPTF 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.